



Figure S3

Figure S3: Galunisertib (LY-2157299) treatment in normal CD34+ cells.

CB CD34+ cells were treated with TGF-β1 or galunisertib (Inh) alone or TGF-β1 and galunisertib (TGF-β1+Inh) in combination. (A-B) qRT-PCR analysis was performed to evaluate the expression level of miR-382-5p and SOD2 at 24 hours after treatments. U6 snRNA and GAPDH were used as internal controls. Untreated cells were used to normalize the data. (C) Level of ROS production measured by DCF staining 24 hours after TGF-β1/TGF-β1+ Inh/Inh treatments. The results are representative of three independent experiments and are expressed as the mean ± SEM. 2-tailed Student t test: **, P<.01 versus untreated cells; *, P<.05 versus untreated cells. #, P<.05 versus TGF-β1 treated cells.

Abbreviations: RQ, relative quantity; SOD2, superoxide dismutase 2; TGF-β1, transforming growth factor β1; Inh, inhibitor (galunisertib); DCF, dichloro-fluorescein.